Preliminary experience: Ln a consecutive case series (level V evidence
) involving 10 recipients of unilateral lung transplantation (LT) with
bronchiolitis obliterans, in conjunction with Fujisawa protocol 93-0-
003, the physiologic responses to FK 506 (tacrolimus) ''rescue'' immun
osuppression were assessed. Recipients were 22+/-18 months post-LT and
demonstrated progressive allograft dysfunction that was refractory to
pulsed-dose methylprednisolone therapy. All recipients received induc
tion immunosuppression with Minnesota antilymphocyte globulin (10 to 1
5 mg/kg/d) for 5 to 10 days, cyclosporine (CsA) (whole-blood Abbott TD
X(TM) fluorescence polarization immunoassay (Abbott Inc, Abbott Park,
IL)=600 to 800 ng/mL), azathioprine (2 mg/kg/d), and prednisone (taper
ed to 0.2 mg/kg/d). The ''rescue'' regimen consisted of oral FK 506 ad
justed to maintain a whole-blood Abbott IMX(TM) microparticle enzyme i
mmunoassay (Abbott Inc, Abbott Park, IL) of 10 to 15 ng/mL with an ini
tial increase in prednisone (1.0 mg/kg/d) during conversion that was s
ubsequently tapered to 0.2 mg/kg/d. Spirometry was pet-formed monthly
in accordance with accepted American Thoracic Society criteria. Recipi
ents were classified in accordance with the International Society for
Heart and Lung Transplantation (ISHLT) ''Working Formulation for Stand
ardization of Nomenclature and for Clinical Staging of Chronic Dysfunc
tion in Lung Allografts'' as stages Ib (n = 2), IIb (n = 4), and IIIb
(n=4) upon entry to the protocol. The Delta FEV1/month relationships d
uring CsA- and FK 506-based regimens were analyzed by linear regressio
n and compared by signed rank test (p<0.05). Results: The Delta FEV1/m
onth slopes were -0.0687+/-0.0221 and +0.0300+/-0.033 L/mo (mean+/-SEM
) for CsA and FK 506, respectively (p=0.037). Although no significant
spirometric improvement was noted in most recipients, no further decli
ne in FEV1 occurred after conversion to FK 506. Recipients with less s
evere chronic dysfunction (ie, obliterative bronchiolitis [OB] stages
Ib and IIb) stabilized their spirometric indexes at higher levels. Two
recipients with OB stage IIIb died of hypercapnic respiratory failure
at 6 and 8 months after conversion. Conclusions: The Delta FEV1/mo sl
opes stabilized after FK 506 conversion. Earlier conversion may be ben
eficial in stabilizing FEV1 at a higher plateau. Significant economic
impact may be anticipated with FK 506 compared to alternative cytolyti
c strategies for OB. However, multicenter prospective controlled inves
tigations are necessary to further address the potential role of FK 50
6 after LT (level I evidence). Furthermore, the ISHLT ''Staging of OB
Syndrome'' may have significant clinical implications vis-a-vis progno
sis and potential therapies.